Iron tissue and excreta changes induced by ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) in dogs.
The use of EDBPHA as a potential iron chelator in cases of hemochromatosis provided impetus for investigating its toxicology. Because a reddish coloration of excreta was observed during subchronic administration of the drug to dogs, measurements of iron concentrations in blood, excreta, and hematopoietic tissues were made. Groups of beagle dogs of both sexes were injected i.v. with EDBPHA doses of 6, 12, or 18 mg/kg or were given capsules containing doses of 30, 100, or 240 mg/kg for 14 days. Control dogs received either saline i.v. or empty gelatin capsules orally. In addition to the monitoring of toxicological effects, iron levels in plasma, urine, feces, liver, spleen, and kidney were monitored before drug, at the end of treatment, and after a 16-day recovery period. In the absence of hemoglobin and hematocrit changes, i.v. EDBPHA reduced renal iron 40% and hepatic iron 15% to 25% without altering splenic iron. Serum iron rose 34% to 54%, urinary iron 80% to 119%, and fecal iron 23% to 41%. Oral EDBPHA did not induce changes in tissue iron or excreta iron, but serum iron was increased 22% to 29%. These alterations in iron concentrations were transient and may be related to iron redistribution and inactivation of drug by liver.
D000818:Animals; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005029:Ethylenediamines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005243:Feces / Q000032:analysis*; D005260:Female; D006432:Hemochromatosis / Q000188:drug therapy*; D007501:Iron / Q000097:blood / Q000378:metabolism* / Q000652:urine; D007668:Kidney / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007928:Lethal Dose 50; D008297:Male
D005029:Ethylenediamines; C011813:ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid); D007501:Iron